Health board conducts a clinical trial of Optimising a Digital Diagnostic Pathway for Heart Failure in the Community

Photo by Alexander Sinn

NHS Greater Glasgow and Clyde is enrolling patients into the clinical trial investigating Optimising a Digital Diagnostic Pathway for Heart Failure in the Community (OPERA).

The primary aim fo this study is to assess the diagnostic accuracy of Artificial Intelligence (AI) analysis of Point of Care (POC) handheld transthoracic echocardiogram images (POC handheld echocardiogram) compared to the current gold-standard of transthoracic echocardiogram images acquired and analysed by a British Society of Echocardiography (BSE) accredited operator, using a standard echocardiogram machine (standard TTE), for the diagnosis of Heart Failure with reduced Ejection Fraction (HFrEF), in patients referred from the community for investigation of suspected new Heart Failure (HF).

The condition is Heart Failure.

A new clinical trial is recruiting patients in the following locations: United Kingdom.

The trial officially began on the January 5, 2021 and is planned to complete on December 31, 2021.

The population that can be enrolled into this study includes adult individuals referred from the community who are awaiting HF diagnostic investigations, including echocardiography, to investigate for a suspected new diagnosis of HF.

Among the excluding conditions appear:

• Individuals less than 18 years of age.
• Individuals who have had an interim echocardiogram for another clinical reason, whilst on the outpatient echocardiogram waiting list for investigation of HF.
• Individuals with a previous ICD-10 diagnosis of HF in any coding position/
• Inability of the participant, in the opinion of the investigators, to understand and/or comply with study procedures, or any conditions that, in the opinion of the investigators, may render the participant unable to understand, attend and/or undergo study visit investigations/
• Inability to read and understand the PIS (provided in English only), and understand the research team

University of Glasgow is the collaborator in this clinical trial.

NHS Greater Glasgow and Clyde is an NHS board in West Central Scotland, created from the amalgamation of NHS Greater Glasgow and part of NHS Argyll and Clyde on 1 April 2006. It is the largest health board in both Scotland, and the UK, which consists of the Council Areas of the City of Glasgow, East Dunbartonshire, East Renfrewshire, Inverclyde, Renfrewshire and West Dunbartonshire.
The board is pioneering the mental health arm of the Scottish Patient Safety Programme.

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT04724200